Kesimpta 20 MG/0.4 ML pen 0.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26F56LK
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,417
Award facts
- Contract value 100% obligated
- $22,417.17 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,417.17 firm fixed-price delivery order to AmerisourceBergen Drug Corp for KESIMPTA 20 mg/0.4 ml pen auto-injectors on December 3, 2025, with completion expected by December 4, 2025. This is a non-set-aside, competitively awarded contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. The product being delivered—KESIMPTA, a monoclonal antibody medication used to treat primary progressive multiple sclerosis—will be distributed from AmerisourceBergen's Conshohocken, Pennsylvania location to support federal medical supply needs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's portfolio of federal contract awards demonstrates extensive capability across multiple therapeutic domains, including specialty medications, vaccines, and medical devices. This delivery order represents a routine fulfillment under the comprehensive SPE2DX vehicle, which positions AmerisourceBergen as a primary pharmaceutical supplier within the DLA's evolving Pharmaceutical Prime Vendor Global Program Generation V framework.
Quick answers
Who was awarded contract SPE2DR26F56LK?
SPE2DR26F56LK was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26F56LK worth?
The government has obligated $22,417 on SPE2DR26F56LK.
Is contract SPE2DR26F56LK an order under another contract?
Yes. SPE2DR26F56LK is a delivery order under SPE2DR25D2006, an indefinite delivery contract.
Was contract SPE2DR26F56LK competed?
The extent of competition for SPE2DR26F56LK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award